Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Assessing compliance with national comprehensive cancer network guidelines for elderly patients with stage III colon cancer: the Fox Chase Cancer Center Partners' initiative.

O'Grady MA, Slater E, Sigurdson ER, Meropol NJ, Weinstein A, Lusch CJ, Sein E, Keeley P, Miller B, Engstrom PF, Cohen SJ.

Clin Colorectal Cancer. 2011 Jun;10(2):113-6. doi: 10.1016/j.clcc.2011.03.007. Epub 2011 Apr 22.

2.

Adjuvant chemotherapy in stage III colon cancer: guideline implementation, patterns of use and outcomes in daily practice in The Netherlands.

van Gils CW, Koopman M, Mol L, Redekop WK, Uyl-de Groot CA, Punt CJ.

Acta Oncol. 2012 Jan;51(1):57-64. doi: 10.3109/0284186X.2011.633930. Epub 2011 Nov 28.

PMID:
22122695
3.

Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.

Kim JY, Kim YJ, Lee KW, Lee JS, Kim DW, Kang SB, Lee HS, Jang NY, Kim JS, Kim JH.

Jpn J Clin Oncol. 2013 Feb;43(2):132-8. doi: 10.1093/jjco/hys195. Epub 2012 Nov 29.

PMID:
23204187
4.

The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.

Pandor A, Eggington S, Paisley S, Tappenden P, Sutcliffe P.

Health Technol Assess. 2006 Nov;10(41):iii-iv, xi-xiv, 1-185. Review.

5.

Development and implementation of a medical oncology quality improvement tool for a regional community oncology network: the Fox Chase Cancer Center Partners initiative.

O'Grady MA, Gitelson E, Swaby RF, Goldstein LJ, Sein E, Keeley P, Miller B, Li T, Weinstein A, Cohen SJ.

J Natl Compr Canc Netw. 2007 Oct;5(9):875-82.

PMID:
17977500
6.

Adherence to treatment guidelines in stage II/III rectal cancer in Alberta, Canada.

Eldin NS, Yasui Y, Scarfe A, Winget M.

Clin Oncol (R Coll Radiol). 2012 Feb;24(1):e9-17. doi: 10.1016/j.clon.2011.07.005. Epub 2011 Jul 30.

PMID:
21802914
7.

Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.

Sanoff HK, Carpenter WR, Martin CF, Sargent DJ, Meyerhardt JA, Stürmer T, Fine JP, Weeks J, Niland J, Kahn KL, Schymura MJ, Schrag D.

J Natl Cancer Inst. 2012 Feb 8;104(3):211-27. doi: 10.1093/jnci/djr524. Epub 2012 Jan 20.

8.

Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials.

Haller DG, O'Connell MJ, Cartwright TH, Twelves CJ, McKenna EF, Sun W, Saif MW, Lee S, Yothers G, Schmoll HJ.

Ann Oncol. 2015 Apr;26(4):715-24. doi: 10.1093/annonc/mdv003. Epub 2015 Jan 16.

9.

[Postoperative Adjuvant Chemotherapy for Stage III Colon Cancer--Drug Selection, Tolerability, and Safety in Clinical Practice].

Okada K, Sadahiro S, Saito G, Tanaka A, Suzuki T.

Gan To Kagaku Ryoho. 2016 May;43(5):587-92. Japanese.

PMID:
27210088
10.

Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer.

Panchal JM, Lairson DR, Chan W, Du XL.

Clin Colorectal Cancer. 2013 Jun;12(2):113-21. doi: 10.1016/j.clcc.2012.09.007. Epub 2012 Nov 6.

PMID:
23137529
11.

Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.

Schmoll HJ, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Hoersch S, Rittweger K, Haller DG.

J Clin Oncol. 2015 Nov 10;33(32):3733-40. doi: 10.1200/JCO.2015.60.9107. Epub 2015 Aug 31.

PMID:
26324362
12.

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.

de Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ, Cunningham D, Cartwright TH, Hecht JR, Rivera F, Im SA, Bodoky G, Salazar R, Maindrault-Goebel F, Shacham-Shmueli E, Bajetta E, Makrutzki M, Shang A, André T, Hoff PM.

Lancet Oncol. 2012 Dec;13(12):1225-33. doi: 10.1016/S1470-2045(12)70509-0. Epub 2012 Nov 16.

PMID:
23168362
13.

A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study.

Papadimitriou CA, Papakostas P, Karina M, Malettou L, Dimopoulos MA, Pentheroudakis G, Samantas E, Bamias A, Miliaras D, Basdanis G, Xiros N, Klouvas G, Bafaloukos D, Kafiri G, Papaspirou I, Pectasides D, Karanikiotis C, Economopoulos T, Efstratiou I, Korantzis I, Pisanidis N, Makatsoris T, Matsiakou F, Aravantinos G, Kalofonos HP, Fountzilas G.

BMC Med. 2011 Jan 31;9:10. doi: 10.1186/1741-7015-9-10.

14.

Adherence to stage-specific treatment guidelines for patients with colon cancer.

Chagpar R, Xing Y, Chiang YJ, Feig BW, Chang GJ, You YN, Cormier JN.

J Clin Oncol. 2012 Mar 20;30(9):972-9. doi: 10.1200/JCO.2011.39.6937. Epub 2012 Feb 21.

15.

Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.

Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Gilberg F, Rittweger K, Schmoll HJ.

J Clin Oncol. 2011 Apr 10;29(11):1465-71. doi: 10.1200/JCO.2010.33.6297. Epub 2011 Mar 7.

PMID:
21383294
16.

Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial.

Glen H, Cassidy J.

Expert Rev Anticancer Ther. 2008 Apr;8(4):547-51. doi: 10.1586/14737140.8.4.547.

PMID:
18402521
17.

A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: the Pan-European Trial in Adjuvant Colon Cancer 2 study.

Köhne CH, Bedenne L, Carrato A, Bouché O, Popov I, Gaspà L, Valladares M, Rougier P, Gog C, Reichardt P, Wils J, Pignatti F, Biertz F.

Eur J Cancer. 2013 May;49(8):1868-75. doi: 10.1016/j.ejca.2013.01.030. Epub 2013 Apr 6.

PMID:
23571150
18.

Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer.

Boland GM, Chang GJ, Haynes AB, Chiang YJ, Chagpar R, Xing Y, Hu CY, Feig BW, You YN, Cormier JN.

Cancer. 2013 Apr 15;119(8):1593-601. doi: 10.1002/cncr.27935. Epub 2012 Dec 21.

19.

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.

André T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scriva A, Hickish T, Tabernero J, Van Laethem JL, Banzi M, Maartense E, Shmueli E, Carlsson GU, Scheithauer W, Papamichael D, Möehler M, Landolfi S, Demetter P, Colote S, Tournigand C, Louvet C, Duval A, Fléjou JF, de Gramont A.

J Clin Oncol. 2015 Dec 10;33(35):4176-87. doi: 10.1200/JCO.2015.63.4238. Epub 2015 Nov 2.

PMID:
26527776
20.

Assessing the initiation and completion of adjuvant chemotherapy in a large nationwide and population-based cohort of elderly patients with stage-III colon cancer.

Hu CY, Delclos GL, Chan W, Du XL.

Med Oncol. 2011 Dec;28(4):1062-74. doi: 10.1007/s12032-010-9644-7. Epub 2010 Aug 17.

PMID:
20714945

Supplemental Content

Support Center